Skip to main content

Table 3 Summary of eligible studies on bone health, n = 3 studies

From: Late effects of high-dose methotrexate treatment in childhood cancer survivors—a systematic review

First author
Year
Country
Final cohort (male:female); diagnosis
Cohort description
Age at diagnosis [years] Follow-up [years] Method Effect of HD-MTX
Lequin et al. 2002
The Nether-lands
21 (12:9); ALL Males: mean 6.3 ± 3.5 Mean 9.6 (range 7.9–11.4) DXA lumbar spine and total body (z-Score): BMD, BMDvol continuous variables Group I vs. control group:
▪BMD, BMDvol: no sign. difference
Study group:
▪Group I: HD-MTX (n = 21)
Females: mean 4.6 ± 2.7 Follow-up: since end of treatment
Control group:
▪nrv
Tillmann et al. 2002
UK
28 (17:11); ALL Study group: N/A Mean 4.5 (range 1.5–7.1) DXA lumbar spine and total body (z-Score): BMDvol continuous variables Group I vs. II:
▪Lumbar BMDvol: no sign. Difference (trend: lower BMDvol in group I)
Study group:
▪Group I: HD-MTX (n = 18)
▪Group II: No HD-MTX (n = 10)
age at testing: mean 10.7 ± 2.1 (range 5.7–14.7) Follow-up: since end of treatment
van der Sluis et al. 2000
The Netherlands
23 (13:10); ALL Mean 5.4 (range 1.9–12.4) Mean 9.6 (range 7.9–11.4) DXA lumbar spine and total body (z-Score): BMD, BMDvol continuous variables Group I vs. control group:
▪BMD, BMDvol: no sign. difference
Study group:
▪Group I: HD-MTX (n = 23)
Control group:
▪nrv
Follow-up: since end of treatment
  1. ALL acute lymphoblastic leukemia, BMD bone mineral density, BMDvol volumetric bone mineral density, DXA dual-energy x-ray absorptiometry, HD-MTX high-dose methotrexate, n number, N/A missing information, nrv normal reference values, sign. significant(ly)